Retatrutide

TRIPLE agonist for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and GCG (glucagon receptors)

• Average weight loss of 24-29%

• Management of type 2 diabetes

• Management of chronic weight problems

• Improves glycemic control

• Slows gastric emptying

• Appetite suppressant

• Increases energy expenditure

• Boosts metabolism

• Promotes breakdown of stored visceral fat

**Dosing Schedule:

• 2.5mg (10mg vial needed)

• 5mg (20mg vial needed)

• 7.5mg (30mg vial needed)

• 10mg (40mg total vials needed)

• 12.5mg (50mg total vials needed)

• 15mg (60mg vial needed)

Intended for research use only.